scispace - formally typeset
S

Steven M. Foltz

Researcher at Washington University in St. Louis

Publications -  15
Citations -  2976

Steven M. Foltz is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 9, co-authored 12 publications receiving 1725 citations. Previous affiliations of Steven M. Foltz include Virginia Commonwealth University.

Papers
More filters
Journal ArticleDOI

Oncogenic Signaling Pathways in The Cancer Genome Atlas

TL;DR: This work charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity.
Journal ArticleDOI

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

TL;DR: Gene fusions represent an important class of somatic alterations in cancer, and integration of gene expression, copy number, and fusion annotation data revealed that fusions involving oncogenes tend to exhibit increased expression, whereas fusion involving tumor suppressors have the opposite effect.
Journal ArticleDOI

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

David J. Clark, +224 more
- 31 Oct 2019 - 
TL;DR: A large-scale proteogenomic analysis of ccRCC is reported to discern the functional impact of genomic alterations and provides evidence for rational treatment selection stemming fromccRCC pathobiology.
Journal ArticleDOI

ClonEvol: clonal ordering and visualization in cancer sequencing.

TL;DR: ClonEvol outperformed three of the state of the art tools for clonal evolution inference, showing more robust error tolerance and producing more accurate trees in a simulation, and has broad applicability for longitudinal monitoring of clonal populations in tumor biopsies, or noninvasively, to guide precision medicine.
Journal ArticleDOI

Systematic discovery of complex insertions and deletions in human cancers

TL;DR: Structural analyses support findings of previously missed, but potentially druggable, mutations in the EGFR, MET and KIT oncogenes and indicate the critical importance of improving complex indel discovery and interpretation in medical research.